Rosuvastatin is highly effective in patients with metabolic syndrome

Rosuvastatin is highly effective in patients with metabolic syndrome – Meetings

Rosuvastatin (Crestor) is significantly more effective at lowering LDL cholesterol than atorvastatin, simvastatin and pravastatin, according to new research presented at the IDF Congress in August. In addition, significantly more patients treated with rosuvastatin reached their European and US LDL cholesterol goals than the most commonly prescribed doses of other statins.

The MERCURY study investigated 1342 patients with elevated LDL cholesterol and the metabolic syndrome. Lead investigator of the group, Professor Steen Stender (Gentoffe Hospital, Denmark) commented that the data showed that rosuvastatin was a ‘highly effective treatment for controlling the lipid risk factors of LDL cholesterol, HDL cholesterol and triglycerides’ in patients with metabolic syndrome.

The investigators also found that treatment with rosuvastatin led to beneficial changes in HDL cholesterol and triglyceride levels.

COPYRIGHT 2003 S.B. Communications

COPYRIGHT 2004 Gale Group